3Daniel A, Hussar. New drug of 1996. A record total 41 new therapertic agents reached the US market for the first time in 1996. J Am Pharm Assoc, 1997, 37(2) :193.
4Shishido H, Nagal H, Kurashima A, et al. A study on in vitro antibacterial activity and clinical usefulness in respiratory tract infections of panipenem/betamipron antibioctic. Jpn J Antibiot, 1992,45(2): 143.
5Shirrmmdo K, Oka S, Goto M. Anfimiembinl activity of panipenem on Stnphyloeoeeus aureus and Pseudomonas aeruginosa in i vitro pharmaeokinetie model in eomparison with imipenem. Chemotherapy (Tokyo), 1991,39 (Suppl 3) :75.
6Yamamura N, Imura K, Naganuma H, et al. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproie acid in rats . Drug Metab Dispos, 1999,27(6) :724.
7Sumita Y, Fukasawa M. Transient carbapenem resistance induced by salicylate in pseudomonas aeruginosa associated with suppression of outer membrane protein D2 synthesis. Antimicrob Agents Chemother, 1993,37(2) :2743.
8Pitkin DH, Sheikh L, Nadler HL. Comparative in vitro activity of meropenem versus other extended - spectrum antimicrobials against randomly chosen and selected resistant clinical isolated tested in 26 North American Centers. Clin Infect Dis, 1997, 24(Suppl 2) :S238.
2Farra A, Islam S, Stralfors A, et al. Role of outer membrane pro- tein OprD and pencillin - binding proteins in resistance of pseud- omonas aemginosa to imipenem and meropenem[ J]. Intj Antimi- crob Agents,2008,31 (5) :427 -433.
